Therapies targeting vascular endothelial growth factor receptor (VEGF), mammalian target of rapamycin, and sorafenib may benefit patients with Xp11.2 tRCC (13). The gene discussed is VEGFA; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.